跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 17 天前AI 评分33

达萨利亚药物sevasemten肌营养不良临床试验失败

Servier's $1.5B bet on Edgewise drug fails five months in

AI 导读

达萨利亚公司斥资15.5亿美元购入的肌营养不良药物sevasemten在关键试验中失败。该试验仅进行五个月即宣告失败。

正文

The mus­cu­lar dy­s­tro­phy drug that Servi­er bought for $1.55 bil­lion up­front has al­ready failed its piv­otal tri­al.

The drug, called sevasemten, failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news